Unofficial Committee of Equity Holders of Penick Pharmaceutical, Inc. v. McManigle Ex Rel. Penick Pharmaceutical, Inc. (In Re Penick Pharmaceutical, Inc.)

227 B.R. 229, 1998 Bankr. LEXIS 1555, 1998 WL 839743
CourtUnited States Bankruptcy Court, S.D. New York
DecidedNovember 30, 1998
Docket19-22153
StatusPublished
Cited by4 cases

This text of 227 B.R. 229 (Unofficial Committee of Equity Holders of Penick Pharmaceutical, Inc. v. McManigle Ex Rel. Penick Pharmaceutical, Inc. (In Re Penick Pharmaceutical, Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Unofficial Committee of Equity Holders of Penick Pharmaceutical, Inc. v. McManigle Ex Rel. Penick Pharmaceutical, Inc. (In Re Penick Pharmaceutical, Inc.), 227 B.R. 229, 1998 Bankr. LEXIS 1555, 1998 WL 839743 (N.Y. 1998).

Opinion

*230 MEMORANDUM. DECISION GRANTING DEFENDANT’S MOTION FOR SUMMARY JUDGMENT AND DISMISSING ADVERSARY PROCEEDING

BURTON R. LIFLAND, Bankruptcy Judge.

Before me are the cross-motions for summary judgment of, respectively, (1) the Defendant, Drew McManigle (the “Trustee”), the Chapter 11 Trustee of Penick Pharmaceutical, Inc, (“PPI”) and its subsidiary, Pen-ick Corporation (the “Debtor” and together with PPI, the “Debtors”) and (2) the Plaintiff, the Unofficial Committee of Equity Holders of PPI (the “Committee”). For the reasons set forth below, I grant the Trustee’s motion and deny that of the Committee. Background

Except as hereinafter noted, the relevant facts are not in dispute. On June 9, 1994 (the “Petition Date”), the Debtors filed chapter 11 petitions in this court. The cases were consolidated for procedural purposes only and are being jointly administered. From the Petition Date until April 28, 1997, the Debtors continued to operate as debtors in possession. However, on April 28, 1997, this court appointed the Trustee as chapter 11 trustee pursuant to section 1104 of the Bankruptcy Code. Both pre- and post-petition, the Debtor has been engaged in the manufacture and sale of pharmaceutical products and in research and development with respect thereto.

On March 17,1998, the Committee filed its complaint herein seeking a declaration that a certain new process relating to the manufacture of opium derivatives (the “Process”) is not the property of the bankruptcy estate of the Debtor but is rather the property of the Debtor, free and clear of all claims of the Trustee, creditors and any other entity. Subsequently, the Trustee filed his motion for summary judgment and a determination that the Process is property of the estate and the Committee cross-moved for summary judgment on its claim.

The Process is the invention of Bao-Shan Huang (“Dr. Huang”), Yansong Lu (“Mr. Lu”), Ben-Yi Ji. (“Dr. Ji” and together with Dr. Huang and Mr. Lu, the “Employee Inventors”) and Aris P. Christodoulou (“Dr. Christodoulou” and together with the Employee Inventors, the “Inventors”). Dr. Christodoulou was, at all relevant times until May 9, 1997, when he resigned, an officer and director of the Debtor. He is a shareholder of PPI and a member of the Committee. Dr. Huang was employed by the Debtor as a consultant to work in its research and development department (the “R & D Department”) in 1994. In connection therewith, on May 10, 1994 1 he signed an Employee Confidentiality and Invention Assignment Agreement containing provisions in the following terms:

2. Employee shall disclose promptly to Employer any and all INVENTIONS conceived or made by him/her during his/her employment with Employer, whether or not made during his/her hours of employment or with the use of Employer facilities, materials, or personnel, and whether made solely or jointly with others, and hereby assigns all of his/her entire right, title and interest in any such INVENTIONS to Employer. As used herein, the term INVENTIONS means any and all developments, innovations, discoveries, improvements and ideas, whether patentable or not.
3. Employee shall, whenever requested to do so by Employer, execute any applications, confirmatory assignment documents, or other instruments which Employer shall consider necessary, to apply for and obtain Letters Patent in the United States, or any foreign country, and shall take such other action at Employer’s expense as Employer *231 deems necessary to protect Employer’s interests in the INVENTIONS.

The agreement was signed by Dr. Christo-doulou, as director, on behalf of the Debtor. In December of that year, Dr. Huang formulated certain synthetic routes for the Process. In June 1995, Dr. Huang was hired by the Debtor as an employee in the R & D Department and in that capacity, in January 1996, conducted the first laboratory test of the Process. In October 1996, Dr. Ji and Mr. Lu were hired by the Debtor, initially as consultants and then as employees in the R & D Department. Both signed Employee Confidentiality and Invention Assignment Agreements containing terms identical to those in Dr. Huang’s Employee Confidentiality and Invention Assignment Agreement set forth above. Again, these agreements were signed by Dr. Christodoulou, as director, on behalf of the Debtor. Dr. Ji and Mr. Lu developed certain intermediate synthetic routes used in the Process. The respective fees and salaries of the Employee Inventors were paid by the Debtor’s bankruptcy estate and laboratories, chemicals and equipment belonging to such estate were used in researching and developing the Process. 2 Dr. Christodoulou’s part in the invention of the Process was to conceptualize the use of morphine as a starting material for the preparation of certain opium derivatives.

The Debtor filed the first provisional application for the Process with the United States Patent & Trademark Office (the “P & TO”) on July 26, 1996, the second provisional patent application for the Process with the P & TO on April 29, 1997 and the regular patent application for the Process with the P & TO on July 11, 1997. The Debtor’s basic patent application was allowed by the P & TO and the Debtor is awaiting a response from the P & TO with respect to six divisional patent applications arising from the regular patent application. The Debtor paid all costs and expenses in connection with such applications, including in respect of the hiring of special patent counsel, Burgess, Ryan & Wayne, whose appointment as special counsel to the Trustee was approved by this court on July 22,1997.

Meanwhile, by an Assignment of Application for Patent (the “Assignment”) dated July 8 and 9, 1997, “in consideration of ... $1.00 ... and other valuable consideration,” the Inventors assigned to “Penick Corporation” their interest in the Process and the patent application and Letters Patent relating thereto, in the case of the Employee Inventors, in accordance with the terms of their respective Employee Confidentiality and Invention Assignment Agreements. Discussion

Federal Rule of Civil Procedure 56(c), made applicable to bankruptcy proceedings by Federal Rule of Bankruptcy Procedure 7056, provides that summary judgment is proper “if the pleadings, depositions, answers to interrogatories and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to judgment as a matter of law.” Fed.R.Civ.P. 56(c); see Celotex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986); Gallo v. Prudential Residential Servs., 22 F.3d 1219, 1223 (2d Cir.1994).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
227 B.R. 229, 1998 Bankr. LEXIS 1555, 1998 WL 839743, Counsel Stack Legal Research, https://law.counselstack.com/opinion/unofficial-committee-of-equity-holders-of-penick-pharmaceutical-inc-v-nysb-1998.